Drug intelligence / Profile preview

CO-CoVac-01

Development stage: Preclinical
Lead developer: COBIK
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics

Overview

CO-CoVac-01 is a nanoparticle-based COVID-19 vaccine candidate developed by COBIK, a Slovenian biotechnology company. The vaccine utilizes a platform of coronavirus-like particles (CoVLPs) derived from SARS-CoV-2 structural proteins, designed to mimic the virus's structure and elicit a protective immune response. Currently in preclinical development, the candidate is intended to provide a next-generation approach to COVID-19 immunization, potentially offering broad protection against emerging SARS-CoV-2 variants.

Other names: COBIK SARS-CoV-2 nanoparticle vaccine

Beyond the preview

Go deeper on CO-CoVac-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CO-CoVac-01.

Explore the full profile